Toboroz
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Macarena I. De La Fuente (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Georgios Pongas (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Navya Nair (principal investigator)
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· 3. fázis· NRG Oncology· Forrás
Contact: Alan Dal Pra (principal investigator)
Toboroz
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
NCT06661915· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Terrence J. Bradley (principal investigator)
Toboroz
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06860594· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Macarena I. De La Fuente (principal investigator)
Toboroz
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Janaki N. Sharma (principal investigator)
Toboroz
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481· 3. fázis· NRG Oncology· Forrás
Contact: Morgan Freret (principal investigator)
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Toboroz
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Michele Stanchina (principal investigator)
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Emily E. Jonczak (principal investigator)
Toboroz
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jose Lutzky (principal investigator)
Toboroz
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)
Toboroz
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: James E. Hoffman (principal investigator)
Toboroz
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
NCT05886049· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Sangeetha Venugopal (principal investigator)
Toboroz
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Jashodeep Datta (principal investigator)
Fut, nem toboroz
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Janaki N. Sharma (principal investigator)
Toboroz
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Gretel Terrero (principal investigator)
Fut, nem toboroz
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Frances Valdes-Albini (principal investigator)
Fut, nem toboroz
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
NCT05828082· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Agustin Pimentel (principal investigator)
Fut, nem toboroz
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
NCT05724108· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)
Toboroz
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
NCT05432804· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Macarena I. De La Fuente (principal investigator)
Fut, nem toboroz
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Gregory J. Kubicek (principal investigator)
Toboroz
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
NCT04665739· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Lawrence M. Negret (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
NCT05198830· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT05646316· 3. fázis· NRG Oncology· Forrás
Contact: Abdulrahman Sinno (principal investigator)
Fut, nem toboroz
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
NCT05241860· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Peter J. Hosein (principal investigator)
Fut, nem toboroz
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· 2/3. fázis· NRG Oncology· Forrás
Toboroz
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
NCT04840602· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Georgios Pongas (principal investigator)
Fut, nem toboroz
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
NCT04941287· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
NCT04708418· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT04633239· 1. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Nkiruka Ezenwajiaku (principal investigator)
Fut, nem toboroz
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046· 1. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
NCT04585958· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Abdulrahman Sinno (principal investigator)
Toboroz
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Elizabeth A. Nicolli (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
NCT04216316· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Showing 50 of 108.